Lack of BRAF V600E protein expression in primary central nervous system lymphoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 21, Issue 4, 2013, Pages 351-353

  Berghoff, Anna S ^a,b   Capper, David ^a,c,d   Preusser, Matthias ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

BRAF V600E; mutation specific monoclonal mouse antibody VE1; PCNSL; primary central nervous system lymphoma; v raf murine sarcoma viral oncogenes homolog B1

Indexed keywords

B RAF KINASE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS ONCOGENE;

ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84880924090     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182688e59     Document Type: Article

References (19)

1. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6:313-319.
2. Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385-394.
3. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS Mutations in Human Lung Cancer and Melanoma. Cancer Res. 2002;62:6997-7000.
4. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
5. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma. Am J Surg Pathol. 2012;36:844-850.
6. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairycell leukemia. N Engl J Med. 2011;364:2305-2315.
7. Andrulis M, Penzel R, Weichert W, et al. Application of a BRAF V600E Mutation-specific Antibody for the Diagnosis of Hairy Cell Leukemia. Am J Surg Pathol. 2012. [Epub ahead of print].
8. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116: 1919-1923.
9. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
10. Dietrich S, Glimm H, Andrulis M, et al. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038-2040.
11. Neyns B, Seghers AC, Wilgenhof S, et al. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 2012. [Epub ahead of print].
12. Falchook GS, Long GV, Kurzrock R, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet. 2012;379:1893-1901.
13. Deckert M, Paulus W. World Health Classification of Tumours the Central Nervous System. Lyon: IARC Press; 2007:188-192.
14. Deckert M, Engert A, Bruck W, et al. Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia. 2011;25: 1797-1807.
15. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103: 275-282.
16. Preusser M, Woehrer A, Koperek O, et al. Primary central nervous system lymphoma: A clinicopathological study of 75 cases. Pathology. 2010;42:547-552.
17. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 2011;122:11-19.
18. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases. Acta Neuropathol. 2012;123: 223-233.
19. Bellinzona M, Roser F, Ostertag H, et al. Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: A series of 33 cases. Eur J Surg Oncol. 2005;31:100-105.